{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T16:25:13Z","timestamp":1777134313375,"version":"3.51.4"},"reference-count":32,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","em-consulte.com","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Neurology"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/s1474-4422(15)00336-1","type":"journal-article","created":{"date-parts":[[2015,12,22]],"date-time":"2015-12-22T19:58:45Z","timestamp":1450814325000},"page":"154-165","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":254,"title":["Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial"],"prefix":"10.1016","volume":"15","author":[{"given":"Joaquim J","family":"Ferreira","sequence":"first","affiliation":[]},{"given":"Andrew","family":"Lees","sequence":"additional","affiliation":[]},{"given":"Jos\u00e9-Francisco","family":"Rocha","sequence":"additional","affiliation":[]},{"given":"Werner","family":"Poewe","sequence":"additional","affiliation":[]},{"given":"Olivier","family":"Rascol","sequence":"additional","affiliation":[]},{"given":"Patr\u00edcio","family":"Soares-da-Silva","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"issue":"suppl 3","key":"10.1016\/S1474-4422(15)00336-1_bib1","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1002\/mds.23829","article-title":"The Movement Disorder Society evidence-based medicine review update: treatments for the motor symptoms of Parkinson's disease","volume":"26","author":"Fox","year":"2011","journal-title":"Mov Disord"},{"key":"10.1016\/S1474-4422(15)00336-1_bib2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1468-1331.2012.03866.x","article-title":"Summary of the recommendations of the EFNS\/MDS-ES review on therapeutic management of Parkinson's disease","volume":"20","author":"Ferreira","year":"2013","journal-title":"Eur J Neurol"},{"key":"10.1016\/S1474-4422(15)00336-1_bib3","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/mds.26125","article-title":"Clinical spectrum of levodopa-induced complications","volume":"30","author":"Aquino","year":"2015","journal-title":"Mov Disord"},{"key":"10.1016\/S1474-4422(15)00336-1_bib5","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/mds.20279","article-title":"Impact of the motor complications of Parkinson's disease on the quality of life","volume":"20","author":"Chapuis","year":"2005","journal-title":"Mov Disord"},{"issue":"7 suppl","key":"10.1016\/S1474-4422(15)00336-1_bib6","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1212\/WNL.0b013e31819908ce","article-title":"Treatments for Parkinson disease\u2014past achievements and current clinical needs","volume":"72","author":"Poewe","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/S1474-4422(15)00336-1_bib7","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/S1474-4422(06)70521-X","article-title":"Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications","volume":"5","author":"Olanow","year":"2006","journal-title":"Lancet Neurol"},{"key":"10.1016\/S1474-4422(15)00336-1_bib8","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s40265-014-0343-0","article-title":"Catechol-O-methyltransferase inhibitors in Parkinson's disease","volume":"75","author":"Muller","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/S1474-4422(15)00336-1_bib9","article-title":"Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease","volume":"4","author":"Deane","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/S1474-4422(15)00336-1_bib11","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1021\/jm1001524","article-title":"Discovery of a long-acting, peripherally selective inhibitor of catechol-O-methyltransferase","volume":"53","author":"Kiss","year":"2010","journal-title":"J Med Chem"},{"key":"10.1016\/S1474-4422(15)00336-1_bib12","series-title":"Emerging drugs and targets for Parkinson's disease (RSC drug discovery)","first-page":"83","article-title":"Catechol-O-methyl-transferase inhibitors: present problems and relevance of the new ones","author":"Palma","year":"2013"},{"key":"10.1016\/S1474-4422(15)00336-1_bib13","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/jcc.22926","article-title":"Computation of the binding affinities of catechol-O-methyltransferase inhibitors: multisubstate relative free energy calculations","volume":"33","author":"Palma","year":"2012","journal-title":"J Comput Chem"},{"key":"10.1016\/S1474-4422(15)00336-1_bib14","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/ene.12666","article-title":"Effect of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor fluctuations in patients with Parkinson's disease","volume":"22","author":"Ferreira","year":"2015","journal-title":"Eur J Neurol"},{"key":"10.1016\/S1474-4422(15)00336-1_bib15","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s00228-014-1701-2","article-title":"Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations","volume":"70","author":"Rocha","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/S1474-4422(15)00336-1_bib16","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","article-title":"Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases","volume":"55","author":"Hughes","year":"1992","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/S1474-4422(15)00336-1_bib17","series-title":"Recent developments in Parkinson's disease","first-page":"153","article-title":"Unified Parkinson's Disease Rating Scale","author":"Fahn","year":"1987"},{"key":"10.1016\/S1474-4422(15)00336-1_bib18","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/00002826-200003000-00003","article-title":"A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia","volume":"23","author":"Hauser","year":"2000","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/S1474-4422(15)00336-1_bib19","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/jnnp.73.6.629","article-title":"The Parkinson's disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson's disease","volume":"73","author":"Chaudhuri","year":"2002","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"suppl 1","key":"10.1016\/S1474-4422(15)00336-1_bib20","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1007\/PL00007730","article-title":"PDQ-39: a review of the development, validation and application of a Parkinson's disease quality of life questionnaire and its associated measures","volume":"245","author":"Peto","year":"1998","journal-title":"J Neurol"},{"key":"10.1016\/S1474-4422(15)00336-1_bib21","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1002\/mds.21596","article-title":"The metric properties of a novel non-motor symptoms scale for Parkinson's disease: results from an international pilot study","volume":"22","author":"Chaudhuri","year":"2007","journal-title":"Mov Disord"},{"key":"10.1016\/S1474-4422(15)00336-1_bib22","series-title":"ECDEU assessment manual for psychopharmacology","first-page":"218","article-title":"Clinical global impressions","author":"Guy","year":"1976"},{"key":"10.1016\/S1474-4422(15)00336-1_bib23","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","article-title":"The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults","volume":"168","author":"Posner","year":"2011","journal-title":"Am J Psychiatry"},{"key":"10.1016\/S1474-4422(15)00336-1_bib24","first-page":"5","article-title":"Compulsive buying: descriptive characteristics and psychiatric comorbidity","volume":"55","author":"Christenson","year":"1994","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/S1474-4422(15)00336-1_bib26","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/sim.3495","article-title":"A graphical approach to sequentially rejective multiple test procedures","volume":"28","author":"Bretz","year":"2009","journal-title":"Stat Med"},{"key":"10.1016\/S1474-4422(15)00336-1_bib27","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1002\/sim.2716","article-title":"Tree-structured gatekeeping tests in clinical trials with hierarchically ordered multiple objectives","volume":"26","author":"Dmitrienko","year":"2007","journal-title":"Stat Med"},{"key":"10.1016\/S1474-4422(15)00336-1_bib28","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/wnf.0b013e3180645cb0","article-title":"Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity, and motor fluctuations in patients with Parkinson disease","volume":"31","author":"Ferreira","year":"2008","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/S1474-4422(15)00336-1_bib29","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/mds.23638","article-title":"Determination of minimal clinically important change in early and advanced Parkinson's disease","volume":"26","author":"Hauser","year":"2011","journal-title":"Mov Disord"},{"key":"10.1016\/S1474-4422(15)00336-1_bib30","first-page":"467131","article-title":"minimal clinically important difference in Parkinson's disease as assessed in pivotal trials of pramipexole extended release","volume":"2014","author":"Hauser","year":"2014","journal-title":"Parkinsons Dis"},{"key":"10.1016\/S1474-4422(15)00336-1_bib32","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S0140-6736(05)71083-7","article-title":"Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial","volume":"365","author":"Rascol","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/S1474-4422(15)00336-1_bib33","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1212\/WNL.0000000000000340","article-title":"Another face of placebo: the lessebo effect in Parkinson disease: meta-analyses","volume":"82","author":"Mestre","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/S1474-4422(15)00336-1_bib34","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/978-3-662-44519-8_8","article-title":"Great expectations: the placebo effect in Parkinson's disease","volume":"225","author":"Lidstone","year":"2014","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/S1474-4422(15)00336-1_bib35","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1002\/mds.21407","article-title":"Effect of medical and surgical interventions on health-related quality of life in Parkinson's disease","volume":"22","author":"Martinez-Martin","year":"2007","journal-title":"Mov Disord"},{"key":"10.1016\/S1474-4422(15)00336-1_bib36","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1136\/jnnp.69.3.308","article-title":"What contributes to quality of life in patients with Parkinson's disease?","volume":"69","author":"Schrag","year":"2000","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["The Lancet Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1474442215003361?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1474442215003361?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T10:24:59Z","timestamp":1668767099000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1474442215003361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["S1474442215003361"],"URL":"https:\/\/doi.org\/10.1016\/s1474-4422(15)00336-1","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726054684.793529088","asserted-by":"object"}]},"ISSN":["1474-4422"],"issn-type":[{"value":"1474-4422","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial","name":"articletitle","label":"Article Title"},{"value":"The Lancet Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/S1474-4422(15)00336-1","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/S1474-4422(15)00346-4","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}